Faron Pharmaceuticals PLC on Tuesday - Turku, Finland-based developer of cancer immunotherapies - Presents full analysis of positive phase 2 interim data from Bexmab trial at the annual meeting of the Society of Hematology in San Diego. Faron highlights an overall response rate of 80% in refractory or relapsed HMA failed MDS patient population. HMA stands for hypomethylating agents, while MDS stands for myelodysplastic syndromes. Chief Executive Officer Juho Jalkanen says: ‘With this compelling evidence, we are well positioned to advance to the full phase 2 efficacy readout and actively pursue further regulatory interactions to navigate and refine the pivotal pathway for BLA filing.’
Last week Monday, Faron said its Bexmab study may proceed in the UK, while bexmarilimab received an innovation passport from the UK’s Medicines & Healthcare Products Regulatory Agency known as MHRA. Bexmarilimab is an investigational immunotherapy that alters the tumour microenvironment.
Current stock price: 200.00 pence each, up 11% on Tuesday afternoon in London
12-month change: down 31%
Copyright 2024 Alliance News Ltd. All Rights Reserved.
